Section 1: Introduction -- The Tablet That Has to Be Taken Alone

A 54-year-old woman in Bridgetown, Barbados takes levothyroxine 100 mcg every morning. She also takes ferrous sulphate 200 mg twice daily, calcium carbonate 500 mg twice daily, and omeprazole 20 mg daily. She makes coffee before taking her tablets and drinks it within a few minutes of swallowing them. Her TSH has been above range for two consecutive years despite three dose increases.

The levothyroxine is failing to work -- not because the dose is wrong, but because it is being prevented from absorbing. Ferrous sulphate, calcium carbonate, omeprazole, and coffee each independently reduce levothyroxine absorption. She is taking all four, simultaneously, every morning.

This is not an unusual clinical scenario. Levothyroxine has one of the most extensively documented oral absorption interaction profiles in pharmacology. It must be taken on an empty stomach, 30-60 minutes before food, coffee, or other medications. Across Caribbean clinical practice, the instruction is frequently given but rarely followed -- not through negligence, but because the magnitude of the interaction is poorly understood by both clinicians and patients.

Thyroid disease is common in the Caribbean. Hypothyroidism affects approximately 2-5% of the adult population, with higher rates in women and in older adults. Hyperthyroidism is less common but more acutely dangerous, and its pharmacological management -- carbimazole and propylthiouracil -- carries specific risks that require active monitoring. Amiodarone, the antiarrhythmic used in Caribbean practice for atrial fibrillation (Report 15), causes both hypothyroidism and hyperthyroidism through mechanisms that are often unrecognised until significant thyroid dysfunction has developed.

This report covers the full scope of thyroid pharmacology in Caribbean practice: levothyroxine absorption interactions, thyroid function monitoring, antithyroid drug safety, amiodarone-induced thyroid dysfunction, and thyroid disease in pregnancy.

Section 2: Levothyroxine -- The Absorption Problem

2.1 Why levothyroxine absorption is so sensitive

Levothyroxine (thyroxine, T4) is poorly soluble and has a narrow therapeutic window. Small changes in absorption produce clinically significant changes in serum thyroid hormone levels and TSH. The drug is absorbed primarily in the jejunum and ileum, and this absorption is reduced by:

• Divalent and trivalent cations (calcium, iron, magnesium, aluminium) -- which bind levothyroxine in the gut and reduce absorption by 20-40%
• Proton pump inhibitors and H2 antagonists -- which reduce gastric acid, changing the ionisation state of levothyroxine and reducing dissolution
• Coffee (even decaffeinated) -- which reduces absorption by up to 36% when consumed within 60 minutes of the tablet
• High-fibre foods -- which reduce absorption by altering gut transit and binding levothyroxine
• Soya products -- which reduce absorption through an uncertain mechanism; relevant in Caribbean populations consuming soya milk or tofu

2.2 The full list of absorption interactions

The practical instruction: Take levothyroxine on waking, alone, with water, 30-60 minutes before food, coffee, or other medications. All interacting substances should be taken at least 4 hours after levothyroxine wherever possible.

Caribbean practice note: Many patients in the Caribbean take their morning medications as a group -- all tablets at the same time, with breakfast or coffee. This is the most common cause of unexplained levothyroxine under-absorption in practice. Before increasing the levothyroxine dose, confirm the timing of administration.

2.3 Other drugs that affect levothyroxine requirements

Some drugs do not reduce absorption but alter levothyroxine requirements by other mechanisms:

Section 3: Monitoring Thyroid Function -- What the TSH Is Telling You

3.1 TSH interpretation

The thyroid-stimulating hormone (TSH) is the most sensitive indicator of thyroid function. It is inversely related to circulating thyroid hormone levels -- when T4 is low (hypothyroidism), TSH rises; when T4 is high (hyperthyroidism), TSH falls.

After dose change: TSH takes 6-8 weeks to fully reflect a change in levothyroxine dose. Rechecking TSH at less than 6 weeks after a dose change is uninformative -- the result does not reflect the new steady state.

In older adults: TSH targets are slightly higher. A TSH of 1-4 mU/L is appropriate for adults under 65. In adults aged 65-80, a TSH of 1-6 mU/L is acceptable. In adults over 80, some guidelines accept TSH up to 7-8 mU/L -- aggressive treatment to achieve a low-normal TSH in frail elderly patients is associated with increased cardiovascular risk and bone loss.

3.2 Monitoring frequency

Section 4: Hyperthyroidism -- Antithyroid Drug Safety

4.1 Carbimazole

Carbimazole (metabolised to methimazole) is the first-line antithyroid drug across the Caribbean. It inhibits thyroid peroxidase, reducing thyroid hormone synthesis.

The most serious adverse effect -- agranulocytosis:

Agranulocytosis (severe reduction in neutrophil count) occurs in approximately 0.2-0.5% of patients on carbimazole. It is unpredictable, not dose-dependent at standard doses, and can develop within days. Without prompt recognition and treatment, it is potentially fatal from overwhelming infection.

Clinical presentation: Any patient on carbimazole who develops fever, sore throat, or mouth ulcers should be treated as agranulocytosis until proven otherwise. This is not a coincidental viral infection -- it is a drug emergency until a full blood count with differential is checked.

Instruction to every patient starting carbimazole: - Stop the drug immediately if fever, severe sore throat, or mouth ulcers develop - Attend for urgent blood count - Do not wait for a scheduled appointment

Other adverse effects: Rash (up to 5%), arthralgia, headache, hepatotoxicity (rare but serious).

Pregnancy: Carbimazole is associated with aplasia cutis (a scalp defect) and other congenital anomalies in first-trimester exposure. Propylthiouracil is preferred in the first trimester; carbimazole is generally acceptable from the second trimester if PTU is not tolerated.

4.2 Propylthiouracil (PTU)

Propylthiouracil also inhibits thyroid peroxidase and additionally inhibits peripheral conversion of T4 to the more active T3.

Serious adverse effects: - Agranulocytosis (same risk and presentation as carbimazole) - Hepatotoxicity -- PTU carries a higher risk of severe hepatotoxicity than carbimazole. It is associated with fulminant hepatic failure, including fatal cases. Liver function should be monitored during treatment. Patients should be counselled to report jaundice, right upper quadrant pain, or dark urine immediately.

Pregnancy: PTU is preferred over carbimazole in the first trimester because the congenital anomaly risk is lower, though it is not zero.

Section 5: Amiodarone and the Thyroid

Amiodarone (Report 15, Section 5) deserves a dedicated section in any thyroid report. It causes thyroid dysfunction in up to 15% of patients, through mechanisms that are distinct from other drug-thyroid interactions.

5.1 Why amiodarone is so difficult for the thyroid

Each 200 mg amiodarone tablet contains 75 mg of iodine. The recommended daily iodine intake for adults is 150 mcg. A patient on standard amiodarone dosing receives approximately 100 times the recommended daily iodine intake. This massive iodine load overwhelms the thyroid's normal autoregulatory mechanisms.

Amiodarone has a half-life of 40-55 days. Thyroid effects persist for months after the drug is stopped.

5.2 Amiodarone-induced hypothyroidism (AIH)

Excess iodine inhibits thyroid hormone synthesis (Wolff-Chaikoff effect). In susceptible patients -- particularly those with underlying autoimmune thyroid disease (Hashimoto's) -- the thyroid cannot escape this inhibition, resulting in hypothyroidism.

Incidence: 5-10% of patients on amiodarone. Management: Continue amiodarone (if required for cardiac indication). Start levothyroxine. Monitor TSH every 3 months.

5.3 Amiodarone-induced thyrotoxicosis (AIT)

Excess iodine can also stimulate thyroid hormone synthesis (Jod-Basedow phenomenon, Type 1 AIT) or amiodarone may cause direct destructive thyroiditis releasing stored hormone (Type 2 AIT). Both produce hyperthyroidism.

Incidence: 2-5% of patients on amiodarone.

The challenge: AIT is clinically dangerous because: - The hyperthyroid state precipitates or worsens arrhythmias -- including the very arrhythmia for which amiodarone was prescribed - Amiodarone itself blocks T4-to-T3 conversion, masking the usual biochemical pattern of hyperthyroidism - Standard antithyroid treatment is less effective in the iodine-replete state

Management: Requires specialist thyroid and cardiology input. Type 1 AIT: antithyroid drugs. Type 2 AIT: prednisolone. Stopping amiodarone is sometimes required but must be weighed against the cardiac risk.

Monitoring: TSH, free T4, and free T3 before starting amiodarone, then every 3 months for the first year, then annually.

Section 6: Thyroid Disease in Pregnancy

Thyroid disease in pregnancy requires specific management because: - Thyroid hormone requirements increase by 30-50% during pregnancy due to increased thyroxine-binding globulin and increased fetal demand - Untreated hypothyroidism in pregnancy is associated with miscarriage, premature birth, and impaired neurodevelopmental outcomes in the child - Hyperthyroidism in pregnancy carries maternal and fetal risks - Both carbimazole and PTU cross the placenta and can cause fetal hypothyroidism

6.1 Hypothyroidism in pregnancy

Women with known hypothyroidism on levothyroxine typically require a dose increase of 25-50% by the first trimester, often from the moment pregnancy is confirmed. TSH should be checked every 4-6 weeks in the first two trimesters and once in the third.

Target TSH in pregnancy: 0.1-2.5 mU/L in the first trimester; 0.2-3.0 mU/L in the second and third.

6.2 Subclinical hypothyroidism in pregnancy

A TSH above 2.5 mU/L in the first trimester warrants consideration of levothyroxine in pregnancy, even if the pre-pregnancy TSH was within the normal range. TSH requirements tighten in pregnancy.

6.3 Hyperthyroidism in pregnancy

PTU is preferred over carbimazole in the first trimester (Report 5, Section 3). Both drugs cross the placenta and can cause fetal goitre and hypothyroidism -- the lowest effective dose should be used and free T4 should be monitored (not just TSH, which may not reflect fetal thyroid status accurately).

6.4 Postpartum thyroiditis

Postpartum thyroiditis -- transient thyroid inflammation after delivery -- affects approximately 5-10% of women and produces a pattern of initial hyperthyroidism (weeks 1-4 post-partum) followed by hypothyroidism (months 4-8) and then recovery. It is often confused with postnatal depression or postpartum anxiety, as the symptoms (fatigue, mood change, palpitations) overlap. Checking TSH in women with unexplained postpartum symptoms is warranted.

Section 7: The Thyroid Prescribing Checklist

Section 8: About ElesRx

ElesRx flags levothyroxine absorption interactions when concurrent calcium, iron, antacids, or PPIs are identified in a patient's medication list. The system also flags increased levothyroxine requirements when enzyme-inducing drugs (carbamazepine, rifampicin) or oestrogen-containing medications are added, and generates an amiodarone-thyroid monitoring alert when amiodarone is prescribed.

The tool is available at elesrx.com. ElesRx is a product of PIPPS Smart Apps, a division of J.C. Epiphany Limited (Jamaica, est. 1998).

Section 9: Methodology and References

9.1 Data sources

Thyroid pharmacology data is drawn from the ElesRx clinical database, DailyMed, the European Medicines Agency, Health Canada, and published clinical guidelines from the American Thyroid Association and the European Thyroid Association.

9.2 Limitations

Management of amiodarone-induced thyrotoxicosis, thyroid cancer pharmacotherapy, and specialist-level hyperthyroidism management (radioiodine dosing, surgical referral thresholds) are beyond the scope of this report.

9.3 Author and conflict of interest disclosure

This report was authored by Juliet Duncan, BPharm, founder of J.C. Epiphany Limited and developer of ElesRx. The author has a commercial interest in ElesRx. This report is published without an access gate as a contribution to Caribbean clinical education. No external funding was received.

9.4 Citation

Duncan J. The Thyroid Report: Levothyroxine, Thyroid Disease, and the Interactions That Are Missed Every Morning. ElesRx Clinical Reports, Report 16. Published 2027 at elesrx.com/reports/thyroid-report/. J.C. Epiphany Limited, Jamaica.

References

1. Centanni M, Gargano L, Canettieri G, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med. 2006;354(17):1787-1795. doi:10.1056/NEJMoa043903

2. Vita R, Saraceno G, Trimarchi F, Benvenga S. A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations. Endocrine. 2013;43(1):154-160. doi:10.1007/s12020-012-9772-2

3. Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. Eur Thyroid J. 2018;7(4):167-186. doi:10.1159/000490384

4. Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27(3):315-389. doi:10.1089/thy.2016.0457

5. Bogazzi F, Tomisti L, Bartalena L, Aghini-Lombardi F, Martino E. Amiodarone and the thyroid: a 2012 update. J Endocrinol Invest. 2012;35(3):340-348. doi:10.3275/8007